Skip to main content

Virtual Molecular Tumor Board Series

About the Series

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Speakers

Howard McLeod webinar speaker profile image

Howard McLeod, PharmD

Medical Director, Precision Medicine
Geriatric Oncology Consortium

Read more

Dr. Howard McLeod is the Medical Director for Precision Medicine at the Geriatric Oncology Consortium. He is an internationally recognized expert in pharmacogenomics and personalized medicine, having made contributions at the discovery, translation, implementation, and policy levels. He is a Professor at the University of South Florida Taneja College of Pharmacy. He was previously the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He also chaired the Department of Individualized Cancer Management, was a Senior Member in the Department of Cancer Epidemiology, and a State of Florida Endowed Chair in Cancer Research. Dr. McLeod chaired the NHGRI eMERGE network external scientific panel for the past decade and was a recent member of both the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council.

Since 2002, Dr. McLeod has been vice chair for Pharmacogenomics for the major NCI clinical trials group, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr. McLeod is a Fellow of the American Society of Clinical Oncology and the American College of Clinical Pharmacy. Howard has published over 560 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance individualized medicine.

Lincoln Nadauld webinar speaker profile image

Lincoln Nadauld, MD, PhD

Chief, Precision Health and Genomics, Intermountain Healthcare

Read more

Lincoln Nadauld founded the Intermountain Precision Genomics program with a vision of finding solutions to improve health and disease through genomics and precision medicine without increasing costs. With his vision in mind, he oversees the clinical implementation of precision genomics across Intermountain’s 24 hospitals and 160 physician clinics. In addition, he facilitates genomic research to better understand the human genome. Nadauld conceived of and is leading the recently announced Heredigene, Population Study — a collaborative effort with deCODE Genetics in Iceland to collect and perform whole-genome sequencing on 500,000 participants in the Intermountain system. Nadauld’s work in founding Intermountain Precision Genomics was recognized with the Utah Governor’s 32nd Annual Science Medal for Industry, which is the highest civilian award to be bestowed by the state of Utah and honors significant contributions to science and technology. Dr. Nadauld also received the 2020 C2 Catalyst for Precision Medicine award, honoring those who improve personalized treatment for cancer patients. He is married with five children and enjoys attending their many activities and events, as well as water sports, fishing and other athletic pursuits.

Christine Walko webinar speaker profile image

Christine Walko, PharmD, BCOP, FCCP

Research Scientist, Personalized Medicine Specialist
DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center

Read more

Christine M. Walko is a Personalized Medicine Specialist at the DeBartolo Family Personalized Medicine Institute at the H. Lee Moffitt Cancer Center and is also Associate Professor at the University of South Florida Morsani College of Medicine in Tampa, Florida. She is also the Chair of the Clinical Genomics Action Committee (CGAC) and an Attending on the Personalized Medicine Clinical Service at H. Lee Moffitt Cancer Center. Dr. Walko received her Doctor of Pharmacy from Duquesne University in Pittsburgh. She completed a pharmacy practice residency at Virginia Commonwealth University Health System/Medical College of Virginia Hospitals in Richmond, Virginia. She also completed a Hematology/Oncology specialty residency at the University of North Carolina (UNC) Hospitals and Clinics and a Hematology/Oncology fellowship at the University of North Carolina School of Pharmacy in Chapel Hill, North Carolina. She is a board-certified oncology pharmacist.

Jennifer Godden webinar speaker profile image

Jennifer Godden, PharmD, BCOP

Co-Director, Oncology Precision Medicine Program, Aurora Health Care

Read more

Jennifer Godden received her PharmD from the University of Iowa. She completed her post-graduate Pharmacy Practice and Oncology Specialty Residencies at Aurora Health Care. She is currently the Co-Director for the Oncology Precision Medicine program, which she helped implement.

Laura Gonzalez webinar speaker profile image

Laura Gonzalez, PhD

Lead Variant Scientist, Intermountain Healthcare

Read more

Laura Gonzalez is lead variant scientist at Intermountain Healthcare. Prior to joining Intermountain, she held similar roles at Navican and the Virginia Commonwealth University Health System. She holds a BS and PhD from the School of Medicine at the National Autonomous University of Mexico.

Sessions

HRD and DNA Damage Repair

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Initial interest in homologous recombination genes was focused on pathologic mutations associated with risk of inherited breast, prostate, pancreatic, and/or gynecological malignancies. HRD has recently emerged as a biomarker to predict sensitivity to PARP inhibitors, and the identification of these alterations has become important, accordingly.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now

Common Driver Mutations in ‘Off-Label’ Tumor Types

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

US Food and Drug Administration approvals for targeted anticancer therapy are most often for specific types of cancer that possess specific driver mutations. However, the broad application of comprehensive genomic profiling has identified the presence of potential “druggable” driver mutations in malignancies for which FDA approval is not yet obtained.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now

Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Precision medicine has been focused on the presence of activating mutations or gene amplifications. However, recent data has shown that the presence of gene fusions also offer a unique treatment opportunity, with the potential for durable clinical responses.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now

What to Do with a ‘Negative’ Molecular Panel Case

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

The application of comprehensive genomic profiling (CGP) in patients with metastatic solid tumors aims to identify therapeutic options that were not otherwise evident with standard workup. However, CGP -- even when it analyzes patient samples against 500+ potential mutations — does not always identify an actionable target.  In these cases, clinicians still need to develop a care plan based on best evidence and individual patient goals.

Our panel will discuss several of these cases in detail and recommend next steps.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now